Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA by 源��궓洹� et al.
RESEARCH Open Access
Early detection of colorectal cancer based
on presence of methylated syndecan-2
(SDC2) in stool DNA
Yoon Dae Han1, Tae Jeong Oh2, Tae-Ha Chung3, Hui Won Jang3, Youn Nam Kim4, Sungwhan An2 and
Nam Kyu Kim1*
Abstract
Background: Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at
earlier stages. We have previously demonstrated that the presence of SDC2 methylation in stool DNA is significantly
associated with the occurrence of CRC regardless of clinical stage. The aim of this study was to evaluate the clinical
performance of stool DNA-based SDC2 methylation test for CRC.
Methods: Aberrant SDC2 methylation in stool-derived DNA was measured by linear target enrichment (LTE)-quantitative
methylation-specific real-time PCR (qMSP). Duplicate reactions of meSDC2 LTE-qMSP test were performed for stool
samples obtained from CRC patients representing all stages (0–IV) and asymptomatic individuals who were subsequently
underwent colonoscopy examination. To determine the diagnostic value of test in CRC and control groups, sensitivity
and specificity were evaluated by receiver operating characteristic curve analysis.
Results: Of 585 subjects who could be evaluated, 245 had CRC, 44 had various sizes of adenomatous polyps, and 245
had negative colonoscopy results. Stool DNA-based meSDC2 LTE-qMSP showed an overall sensitivity of 90.2% with AUC
of 0.902 in detecting CRC (0–IV) not associated with tumor stage, location, sex, or age (P > 0.05), with a specificity of 90.
2%. Sensitivity for detecting early stages (0-II) was 89.1% (114/128). This test also detected 66.7% (2/3) and 24.4% (10/41)
of advanced and non-advanced adenomas, respectively.
Conclusions: Results of this study validated the capability of stool DNA based-SDC2 methylation test by LTE-qMSP for
early detection of CRC patient with high specificity.
Trial registration: ClinicalTrials.gov, NCT03146520, Registered 10 May 2017, Retrospectively registered; however, control
arm was prospectively registered.
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Background
Colorectal cancer (CRC), the third most common malig-
nancy, is still one of the major causes of cancer-related
mortality worldwide [1, 2]. Its incidence rate is rapidly
increasing in many Asian countries including South Korea
[3]. More surprisingly, the mortality of CRC ranked third
in South Korea based on the 2016 Korean national cancer
statistics [4], meaning that early detection rate was low.
The mean 5-year survival rate for early-stage CRC can be
as high as 90%. However, it can be less than 10% in
patients with metastatic disease [5]. Therefore, early
detection of CRC has emerged as an important global
issue to reduce its high mortality. Many countries have
population-based CRC screening programs [6]. Currently,
colonoscopy is the most accurate screening method for
early diagnosis of CRC. However, its compliance rate
remains very low due to its invasiveness, dietary restric-
tion requirement, and extensive bowel preparation [7, 8].
Although noninvasive fecal immunochemical tests (FIT)
for hemoglobin in stool are available, their sensitivities are
relatively low in detecting stage I CRC (53%) and
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advanced adenomas (≥ 1.0 cm) (27%), with a specifi-
city of 94.6% [9]. Thus, developing highly accurate
CRC screening method using molecular biomarkers
for people who are reluctant to participate in colon-
oscopy examination is urgently needed for early de-
tection of CRC.
Tumorigenesis of CRC arises through accumulation of
genetic and epigenetic abnormalities of the genome [10].
Aberrant DNA methylation at CpG sites of genes is one
of the most common molecular alterations during
tumorigenesis of all types of cancer [11–13]. Aberrant
methylation at specific CpG sites across the genome has
been investigated, and in some instances was applied as
biomarkers for early CRC detection.
Stool specimens from CRC patients usually contain
exfoliated tumor cells. Detecting methylated DNA of a
specific gene in noninvasive stool samples is a promising
option to achieve detection of CRC [14]. Therefore, non-
invasive stool-derived DNA testing has emerged as a
new strategy for detecting of patients with both CRC
and precancerous lesions. Stool DNA-based DNA
methylation assays using several epigenetic biomarkers
such as BMP3, NDRG4, SDC2, SFRP2, TFPI2, and VIM
have been reported as potential noninvasive tools for
early CRC detection [8, 15–21], with sensitivities ranging
from 46 to 90% and specificities ranging from 76.8 to
93%. Cologuard (Exact Sciences), a multi-target stool
DNA test that measures two methylation biomarkers
(BMP3, NDRG4) and seven site mutations of KRAS in
addition to FIT test in stool sample, has been approved
by FDA in the USA [15].
Previously, we have identified aberrant SDC2
methylation frequently occurring in all stages of
CRC through comprehensive methylation analysis of
CRC and normal mucosal tissue samples [22]. More
recently, we have developed a highly sensitive and
accurate methylation DNA assay consisting of quan-
titative methylation-specific real-time PCR (qMSP)
following linear target enrichment (LTE) (named as
meSDC2 LTE-qMSP) for SDC2 methylation and
demonstrated that SDC2 methylation test in stool
DNA has high potential as a diagnostic method for
early detection of CRC [16]. Several studies have
also reported that SDC2 methylation can be sensi-
tively and specifically detected in stool and blood
samples from CRC patients [8, 23–27].
In the present study, we described details of the
analytical performance of meSDC2 LTE-qMSP as a
test for stool DNA samples for early CRC detection.
The aim of this clinical trial was to determine the
clinical performance of the stool DNA-based meSDC2
LTE-qMSP test in detecting CRC in patients at vari-
ous stages and precancerous lesions with various sized
polyps.
Methods
Study design, population, and clinical procedures
This retrospective case and prospective control study
was designed to evaluate the clinical performance of
stool DNA-based meSDC2 LTE-qMSP test. All partici-
pants were enrolled from January 2017 to February 2018
at two clinical sites. Eligible subjects aged 30–80 years
who provided written informed consent were enrolled.
All prospective participants were recruited at Severance
check up, Health Promotion Center, Severance Hospital
(Seoul, South Korea). A single stool sample was col-
lected at least 1 day before routine bowel preparation for
undergoing screening colonoscopy. All colonoscopies
were performed by board-certified endoscopists. Based
on results of complete colonoscopy and pathology
outcome, subjects were categorized as follows: advanced
adenoma (AA, ≥ 1.0 cm), non-advanced adenoma (NA,
< 1.0 cm), hyperplastic or other polyps (HOP), and no
evidence of disease (NED, negative results on colonos-
copy). Retrospective patients who had confirmed CRC
and other gastrointestinal cancers were enrolled from
Severance Hospital, Yonsei University Health System
(Seoul, South Korea). A single stool sample was col-
lected at least one day prior to curative surgery (Fig. 1).
meSDC2 LTE-qMSP results were independently ana-
lyzed by comparison with colonoscopic findings and
pathology outcomes as reference standards. No dietary
or medication restrictions were required. Details of stool
collection procedure are described in Supplemental
Material. All statistical procedures were performed by
the Clinical Trial Center at Severance Hospital. All
personnel involved in experimental work were blinded
to identities of samples.
We excluded participants who had previous history of
CRC, any chemotherapy or radiotherapy, or incomplete
information. The following information was collected:
age, sex, clinical diagnosis, the number and size of
polyps, histology subtype, and date of stool sample
collection.
This clinical study was approved by the Institutional
Review Board (IRB) of Severance Hospital, Yonsei Uni-
versity Health System (IRB No. 1–2016-0068). This clin-
ical trial was sponsored and designed by Genomictree
Inc. (Daejeon, South Korea) and registered at Clinical-
Trials.gov (http://www.clinialtrials.gov, Trial Registration
ID: NCT03146520). All authors had access to the study
data. All authors have reviewed and approved the final
manuscript.
Stool collection, DNA isolation, and bisulfite treatment
Collection paper (JeongHyun MED, South Korea) was
mounted to toilet seat to prevent contamination of toilet
water. At least 2 g of stool was collected from four to
five different spots into 20 ml of preservative buffer
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(Genomictree, Inc., South Korea) using a disposable
spatula for each subject. All stool samples were shipped
at ambient temperature to a central laboratory.
Stool DNA was isolated according to published proto-
col [16] with slight modifications. Briefly, all stool sam-
ples were weighed and thoroughly homogenized in
preservative buffer using a multiple vortex mixer (MIU-
LAB, China). After homogenization, 1~2 g equivalent of
each stool sample was centrifuged at 2000 rpm for
2 min (HA-1000-3, Hanil Science Medical, Daejeon,
South Korea). Supernatants were discarded and then
5.0 ml of GT buffer 1 (Genomictree, Inc. Daejeon, South
Korea) was added to the pellet followed by incubation at
room temperature for 4 min. Samples were then centri-
fuged at 2000 rpm for 2 min (HA-1000-3, Hanil Science
Medical, Daejeon, South Korea) and supernatants were
discarded. Subsequently, 2.0 ml of GT buffer 2 (Geno-
mictree, Inc. Daejeon, South Korea) and 30 μl of pro-
teinase K (0.4 mg/ml, Sigma-Aldrich, St. Louis, MO,
USA) were added to each sample and incubated at 70 °C
for 10 min. These samples were centrifuged at 3000 rpm
for 5 min (HA-1000-3, Hanil Science Medical, Daejeon,
South Korea). Then 0.75 ml of the supernatant was
aliquoted to MaXtract High Density tube (Qiagen,
Hilden, Germany) with 0.75 ml of Tris-saturated
phenol-chloroform-isoamylalcohol (25:24:1 by volume)
(Sigma-Aldrich, St. Louis, USA). Samples were thor-
oughly mixed for 1 min and centrifuged at maximum
speed for 10 min in a microcentrifuge. Then 0.5 ml of
the supernatant was transferred to a new tube contain-
ing 1/10 volume of 3 mol/L sodium acetate (pH 5.2,
Welgene, Gyeongsan, South Korea) and equal volume of
isopropanol (Merck, Darmstadt, Germany). Total nucleic
acid was then precipitated by centrifugation at
maximum speed for 10 min. DNA pellet was washed
with 1.0 ml of 70% ethanol and dried. DNA concentra-
tion was measured using Qubit dsDNA BR assay kit
(Thermo Fisher Scientific, MA, USA).
Stool-derived genomic DNA was chemically modified
with sodium bisulfite using EZ DNA Methylation-Gold kit
(ZYMO Research, USA) according to the manufacturer’s
instructions. Bisulfite-converted DNA was either used im-
mediately for methylation analysis or stored at -− 20 °C
until further use.
Analytical performance of meSDC2 LTE-qMSP test
Analytical performance of meSDC2 LTE-qMSP was deter-
mined based on real-time PCR using Rotor-Gene Q instru-
ment (Qiagen, Germany). To determine the limit of
detection (LoD) for methylated SDC2 DNA, we prepared a
mimic of natural sample matrix of clinical stool samples as
follows. Different amounts (20, 2, 0.2, 0.1, 0.05, 0.02, 0.01,
and 0 ng) of HCT116 genomic DNA as fully methylated
human genomic DNA were diluted into 2.0 μg of SDC2
methylation-negative stool genomic DNA pooled from 20
healthy individuals. Stool genomic DNA from these healthy
individuals was confirmed as SDC2 methylation-negative
by LTE-qMSP. Resulting DNA samples from each concen-
tration were pooled and divided to 24 aliquots so that the
same DNA substrate was utilized for PCR. LoD, the point
at which 95% of replicates of SDC2 methylated DNA were
detected, was determined by Probit analysis [28].
Fig. 1 Study enrollment and flow diagram. The number of enrolled subjects according to diagnosis and the number of stool samples analyzed in
this study. a Samples had insufficient DNA, b Samples either had insufficient human genomic DNA (low COL2A1) or unknown clinical stage
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Reproducibility, repeatability, and lot-to-lot variation
were evaluated according to Clinical Laboratory
Standards Institute guideline EP05-A2 [29]. Tests were
performed using SDC2 methylated HCT116 genomic
DNA with two concentrations (0.5 ng and 0.1 ng)
diluted in 2 μg of SDC2 methylation-negative stool gen-
omic DNA pooled from 20 healthy subjects. SDC2
methylation-negative stool DNA was also included. Re-
producibility was assessed by testing duplicates of each
concentration in two runs for 5 days at two different
sites. Repeatability was evaluated by testing duplicates of
each concentration in two runs for 20 days. The contri-
bution of lot-to-lot variation was analyzed by testing
duplicates of each concentration in two runs for 5 days.
To evaluate the precision, we calculated mean CT, stand-
ard deviation (SD), and % of coefficient of variation
(CV).
Assay specificity of the test kit was assessed by testing
each 0.5 ng of HCT116 and 20 ng of SDC2
methylation-negative genomic DNA spiked with 105 to
106 genome copies of DNA from the following bacteria
and virus potentially found in humans: Candida albi-
cans, Staphylococcus epidermis, Streptococcus pneumo-
niae, Escherichia coli, Human Cytomegalovirus, Herpes
simplex virus 1, Herpes simplex virus 2, and Hepatitis B
virus.
The effect of interfering substances on assay perform-
ance was evaluated using methylated SDC2-positive and
negative stool samples spiked with 23 potential interfer-
ing substances selected based on clinical applications
and diet habits in South Korea (Table 1).
meSDC2 LTE-qMSP test in stool DNA and data analysis
Training of assay procedure and instruments for staff
members were completed before the start of this study.
meSDC2 LTE-qMSP test was performed in duplicate re-
actions for each sample. In order to measure SDC2
methylation, LTE was introduced to specifically enrich
methylated SDC2 target DNA from bisulfite modified
DNA. Additionally, the region lacking CpG dinucleo-
tides of COL2A1 gene was used as a control to estimate
the amount of amplifiable template and adequacy of
bisulfite conversion. A total of 20 μl of reaction mixture
containing 2.0 μg of bisulfite-converted stool DNA,
50 nmol/L each of SDC2 methylation-specific antisense
and COL2A1 gene-specific antisense primers attached to
5′ universal sequence, and 4 μl of 5xAptaTaq PCR mas-
ter mix (Roche Diagnostics, Swiss) was prepared.
Thermal cycling conditions were as follows: 95 °C for
5 min followed by 35 cycles of 95 °C for 15 s and 60 °C
for 60 s.
After LTE, the reaction mixture volume was scaled up
to 40 μl, containing 8 μl of 5xAptaTaq PCR master mix,
250 nmol/L of SDC2 methylation-specific sense primer,
125 nmol/L of SDC2 probe, 125 nmol/L of COL2A1
sense primer, 62.5 nmol/L of COL2A1 probe, and
250 nmol/L of universal sequence primer. Thermal
cycling conditions were as follows: 95 °C for 5 min
followed by 40 cycles of 95 °C for 15 s and 60 °C for
60 s. Heating and cooling rates were 20 °C per second
and 15 °C per second, respectively. For each run,
bisulfite-converted methylated (HCT116) and unmethy-
lated genomic DNA (whole genome amplified human
lymphocyte DNA) were used as methylation controls.
Non-template and non-template bisulfite-converted con-
trols were also included.
PCR reactions for SDC2 and COL2A1 control were
run in a single tube. meSDC2 LTE-qMSP was performed
on a Rotor-Gene Q real time PCR instrument (Qiagen,
Germany). Cycle threshold (CT) value was calculated
using Rotor Gene Q software.
For PCR analysis, SDC2 methylation was detected if
CT was less than 40 cycles. It was not detected if CT was
not measurable [16]. Because stool samples contained
very low levels of human DNA, SDC2 methylation was
called positive if at least one out of two PCR reactions
had detectable methylated SDC2 in order to maximize
clinical sensitivity. Samples were categorized as positive
Table 1 Potentially interfering substances tested in this study
No. Interfering substances Concentration per g stool
1 Kanamycin 2 mg
2 Streptomycin 2 mg
3 Trimethoprim 0.3 mg
4 Vancomycin 3.1 mg
5 Povidone iodine 10 mg
6 Paramoxine hydrochloride 19 mg
7 Berberine hydrochloride 9.23 mg
8 Dulcolax 10 mg
9 Glycerin 10 μl
10 Domperidone 0.14 mg
11 Omeprazole 2.83 mg
12 Cimetidine 2.06 mg
13 Vitamin U 6.84 mg
14 Cefixime 20.47 mg
15 Paracetamol 0.27 mg
16 Levofloxacin hydrochloride 0.15 mg
17 Ibuprofen 0.08 mg
18 Plant DNA 0.5 μg
19 Animal DNA 0.5 μg
20 Vegetable oil 20 μl
21 Bilirubin 450 μM
22 Ethanol 10 μl
23 Aspartame 0.1 mg
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if only one out of two reactions (1/2 algorithm) had de-
tectable SDC2. Samples were considered negative if
SDC2 methylation was not measurable in the two
reactions. Test result was acceptable only when CT value
of COL2A1 was ≤ 31. If COL2A1 was not detected or CT
value was more than 31, the test was re-run.
Statistical analysis
Sample size was calculated using PASS 13.0 program
(NCSS, USA). A sample size of 241 for CRC patients
and 241 for subjects with NED would have a power of
minimum 90% to detect each 10% higher at a one-sided
type I error rate of 0.025 to test the following major
hypotheses:( i) the sensitivity of SDC2 methylation test is
higher than 70%; and (ii) the specificity of SDC2 methy-
lation test is higher than 80%. Thus, samples were col-
lected from 268 CRC patients and 268 subjects with
NED in anticipation of a 10% of sample loss. We also
additionally recruited patients with colorectal polyps (n
= 67), gastric cancers (n = 23), and liver cancers (n = 12).
All statistical analyses of data were performed using SAS
V9.4 (SAS Institute, NC, USA). To calculate sensitivity and
specificity, test results were used in a dichotomous manner:
methylation-positive as ‘1’ and methylation-negative as ‘0.’
Sensitivity and specificity of meSDC2 LTE-qMSP for CRC
detection were estimated as follows:
Sensitivity %ð Þ ¼ true positives=a total number of CRC patients
100
Specificity %ð Þ ¼ true negatives=a total number of subjects with NED
100
The area under receiver operating characteristic
(ROC) curve (AUC) and 95% confidence interval (CI)
were calculated. Demographic and other clinical
characteristics are described as frequency and per-
centile or mean and standard deviation. If P value
was less than 0.05, the result was considered statisti-
cally significant.
Results
Analytical performance of meSDC2 LTE-qMSP test
To determine the LoD for methylated SDC2, meSDC2
LTE-qMSP tests were repeatedly (24 times) performed
using samples with different concentrations of HCT116
genomic DNA. The test was able to detect methylated
SDC2 in stool DNA samples with concentrations as low
as 10 pg (corresponding to ~ 3 diploid genome copies)
in 54.2% (13/24) of replicates (Table 2).
The detection rate for 50 pg of methylated SDC2
DNA was 95.8% (23/24). Probit analysis revealed that
95% LoD of meSDC2 LTE-qMSP test kit was 34.5 pg
(95% CI 18.6–64.1 pg) of methylated SDC2 DNA, corre-
sponding to ~ 20 diploid genome copies (Fig. 2).
Precision evaluation results of meSDC2 LTE-qMSP
test are described in Table 3. It was considered accept-
able if CV was less than 5%. The test showed acceptable
reproducibility, with CV ranging from 1.12 to 2.71%.
Repeatability was also acceptable, with CV ranging from
2.13 to 2.68%. The lot-to-lot variation was low and
acceptable, with CV ranging from 1.12 to 2.71%. Total
precision achieved CV ≤ 5.0% for 20 days with concen-
trations of methylated SDC2 DNA at 100 pg and 500 pg.
For 2.0 μg of SDC2 methylation-negative stool genomic
DNA (40 samples), negative agreement was 100%.
Interfering substances tested in this study had no ef-
fect on test performance of meSDC2 LTE-qMSP. The
test kit showed no cross-reactivity even when excess
amounts (105–106 genome copies) of bacterial and viral
DNA were tested.
Study population
This clinical trial enrolled a total of 634 participants
who visited the hospital for routine colonoscopies or
had confirmed CRC or other gastrointestinal cancer
diagnosis at two clinical sites. A total of 585 (92.3%) of
634 participants had results that could be fully
evaluated.
Of 245 subjects enrolled in group A, 3, 55, 70, 96, and
21 subjects were at stages 0, I, II, III, and IV of CRC, re-
spectively. In group B patients, 41, 3, and 18 subjects
Table 2 LoD of methylated SDC2 DNA using HCT116 genomic DNA samples
DNA concentration (ng) diluted in 2.0 μg of stool genomic DNA SDC2 detected (%) Average CT
20 24 out of 24 (100) 19.01
2.0 24 out of 24 (100) 22.43
0.2 24 out of 24 (100) 25.55
0.1 24 out of 24 (100) 26.92
0.05 23 out of 24 (95.8) 28.62
0.02 22 out of 24 (91.7) 30.08
0.01 13 out of 24 (54.2) 30.39
0 0 out of 24 (0) Not detected
Number of positive test results out of the number of replicates tested and average CT values for various concentrations of methylated SDC2
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were found to have NAs, AAs, and HOP, respectively.
The remaining study participants were subjects with
NED (n = 245). Group C had confirmed diagnosis of gas-
tric cancer (n = 23) or liver cancer (n = 10). Gastric or
liver cancer patients did not undergo colonoscopy exam-
ination. Demographic data for subjects fully evaluated in
this study are shown in Table 4.
Clinical performance of meSDC2 LTE-qMSP test for
detecting CRC in stool-derived DNA
To evaluate the clinical performance of meSDC2
LTE-qMSP test for detecting CRC using stool DNA, we
tested 585 valid samples, including 245 CRCs (0-IV), 3
AAs (≥ 1.0 cm), 41 NAs (< 1.0 cm), 18 HOP, 33 other
gastrointestinal cancers, and 245 subjects with NED.
Of 245 CRC samples, 128 (52.2%) were obtained from
patients with early stages (0–II) of CRC. meSDC2
LTE-qMSP test showed higher frequency and higher
level of aberrant SDC2 methylation in both CRC and
adenomas patients than that in subjects with NED
(Fig. 3).
To evaluate the clinical performance of SDC2 methyla-
tion test in stool DNA to detect CRC (0–IV), ROC curve
was constructed using pre-specified cutoff value [16] of
CT 40 on test results (Fig. 4a). meSDC2 LTE-qMSP test
in stool DNA had an overall sensitivity of 90.2% (221/
245, 95% CI 85.8–93.6%) with AUC of 0.902 (95% CI
0.876–0.928). Sensitivities for individual stages 0, I, II,
III, and IV were 100% (3/3), 85.5% (47/55), 91.4% (64/
70), 89.6% (86/96), and 100% (21/21), respectively
(Fig. 4b). For early stages (0–II) of CRC, sensitivity was
89.1% (114/128, 95% CI 82.3–93.9%). Sensitivity did not
vary significantly (P > 0.05) according to cancer stage,
tumor location, sex, or age. Detection rates of aberrant
SDC2 methylation in stool DNA samples from patients
are summarized in Table 5. meSDC2 LTE-qMSP test de-
tected 66.7% (2/3) and 24.4% (10/41) of AAs and NAs,
respectively. For HOP (< 1.0 cm), detection rate of SDC2
methylation was 26.3% (5/19), similar to the detection
rate for NAs. For gastric and liver cancers, detection
rates of SDC2 methylation were 30.4% (7/23) and 30 (3/
10), respectively (Table 4). For 245 subjects with totally
negative results on colonoscopy, the specificity was
90.2% (221/245, 95% CI 85.8–93.6%) (Fig. 4b). Within
this group, specificities were 90.1% (173/192) and 90.6%
(48/53) for subjects aged < 60 years and ≥ 60 years,
respectively (P = 0.872, Chi-square test). Specificities for
women and men were 90.4% (103/114) and 90.1% (118/
131), respectively (P = 0.943, Chi-square test).
Discussion
CRC screening is crucial because it is highly curable if
the disease is detected at an early stage [5]. We have
developed a highly sensitive and accurate stool
DNA-based SDC2 methylation biomarker test named
meSDC2 LTE-qMSP for early detection of CRC [16]. In
this clinical trial, we evaluated the clinical performance
of meSDC2 LTE-qMSP test for detecting CRC in stool
DNA. Results of this study demonstrated that the test
had high sensitivity and specificity for early detection of
CRC. Thus, stool DNA-based meSDC2 LTE-qMSP test
could be used as an alternative screening option for early
CRC detection. It could be provided to individuals with
average risk for CRC who are reluctant to undergo
colonoscopy.
Conventional screening can effectively reduce death
rate from CRC [30]. Nevertheless, only about 50% and
Fig. 2 LoD of SDC2 methylation test using data derived from
Table 2. The LoD of the test using simulated stool DNA samples was
determined by Probit analysis. The y-axis plots the probability of
methylated SDC2 detection while the x-axis plots spiked HCT116
genomic DNA in a total of 2.0 μg of SDC2 methylation-negative
stool genomic DNA. The estimated LoD (34.5 pg) is indicated by
an arrow
Table 3 Precision evaluation results of the meSDC2 LTE-qMSP test kit
Target HCT116
genomic DNA
concentration
(pg)
Mean CT (%CV)
Reproducibility Repeatability Lot-to-lot variation
Site 1 Site 2 Lot 1 Lot 2
SDC2 100 26.19 (2.71) 25.75 (2.10) 26.1 (2.68) 26.19 (2.71) 25.75 (2.10)
500 23.52 (2.21) 23.15 (1.12) 23.44 (2.13) 23.52 (2.21) 23.15 (1.12)
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30% of the eligible population had participated in CRC
screening programs in the USA and South Korea, re-
spectively [31, 32]. Although colonoscopy and fecal oc-
cult blood test (FOBT) or FIT are the most widely used
screening tools for CRC, these methods are limited by
uptake and adherence [33–35]. Thus, the need for a
noninvasive CRC screening tool using improved bio-
markers has arisen. Early CRC detection will contribute
to better treatment outcomes.
Colorectal tumor cells are constantly exfoliated into
the lumen. Exfoliation of these tumor cells into stool
logically occurs earlier than vascular invasion into blood
Table 4 Demographic features of subjects evaluated in this study
Demographic Clinical diagnosis of prospectively enrolled patients
CRCb Gastric cancer Liver cancer AAa NAa Hyperplastic/other polyp NEDb
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Sex Male 133 (54.3) 9 (39.1) 8 (80.0) 2 (66.7) 22 (53.7) 12 (66.7) 114 (46.5)
Female 112 (45.7) 14 (60.9) 2 (20.0) 1 (33.3) 19 (46.3) 6 (33.3) 131 (53.5)
Age ≤ 49 36 (14.7) 9 (39.1) 1 (10.0) – 11 (26.8) 4 (22.2) 87 (35.5)
50–59 62 (25.3) 7 (30.4) 5 (50.0) 1 (33.3) 17 (41.5) 9 (50.0) 105 (42.9)
60–69 79 (32.2) 5 (21.7) 3 (30.0) 2 (66.7) 12 (29.3) 5 (27.8) 47 (19.2)
≥ 70 68 (27.8) 2 (8.7) 1 (10.0) – 1 (2.4) – 6 (2.4)
Total 245 23 10 3 41 18 245
aAA advanced adenomas (≥ 1.0 cm), NA non-advanced adenomas (< 1.0 cm)
bCRC colorectal cancer, NED no evidence of disease
Fig. 3 Results of SDC2 methylation analysis from two reactions in stool DNA. Distribution of SDC2 methylation was expressed in CT values as
40-CT for each sample. A higher 40-CT represents a higher methylation level of SDC2. It is represented as 0 if the SDC2 methylation was not detectable.
Methylation status of SDC2 gene is plotted as box and whisker plots. CRC colorectal cancer (stage 0–IV), HOP hyperplastic or other polyps, NA
non-advanced adenomas (< 1.0 cm), AA advanced adenomas (≥ 1.0 cm), GC gastric cancer, LC liver cancer, NED no evidence of disease
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during the progression of CRC development [36]. Thus,
measurement of aberrant DNA methylation in stool
samples is ideal for cancer-specific early detection of
CRC [14]. Recently, stool DNA-based biomarker tests
have provided attractive options for noninvasive screen-
ing of CRC [14–20, 37]. Meanwhile, stool matrices
contain exfoliated epithelial cells, diets, bacteria, and
various PCR inhibitors [38–40]. Thus, stool specimens
are difficult for PCR amplification. We have previously
developed a highly sensitive and accurate method called
meSDC2 LTE-qMSP test for methylation analysis of
SDC2 in stool DNA and demonstrated that stool
DNA-based meSDC2 LTE-qMSP test has a high poten-
tial for early CRC detection [16].
In the present study, we first provided details of ana-
lytical performance for meSDC2 LTE-qMSP test. We
then performed a clinical trial to evaluate the perform-
ance of the test using stool DNA. Analytical studies
revealed that the test kit was able to detect methylated
SDC2 at single-digit copy number level. This provides
strong evidence that meSDC2 LTE-qMSP test is
optimized for using stool-derived DNA.
Because CT values for 90.9% of all subjects with NED
were undetectable in the real-time PCR of our pilot
study [16], we determined the sensitivity and specificity
using a pre-specified cutoff (CT 40) for SDC2 methyla-
tion based on the presence or absence of detectable
SDC2 methylation without quantitating methylation in
this clinical trial. To determine methylation status of
SDC2 in stool DNA, we performed PCR in two reactions
to achieve the highest clinical sensitivity. If at least one
out of two PCR reactions from a subject was positive,
the test was considered as positive (1/2 algorithm).
Overall sensitivity of meSDC2 LTE-qMSP test for CRC
(0–IV) was 90.2% with a specificity of 90.2%. These ob-
served clinical sensitivity and specificity results were
consistent with results of our previous study [16]. There
was no significant difference in sensitivity between
early and late stages of CRC (P = 0.679, Chi-square
test). meSDC2 LTE-qMSP test revealed that SDC2
methylation-positive began to appear in patients with pre-
cancerous lesions. It occurred very frequently (over 90%)
in CRC patients regardless of stage. However, it occurred
in 10% of subjects with NED. The results indicate that the
test is very useful for early detection of CRC. Meanwhile,
Niu et al. [8] have recently published results of SDC2
methylation test for stool DNA from Chinese population.
Its overall accuracy for detecting CRC was comparable to
ours. Assuming CRC prevalence of 0.5% in an
average-risk population aged 50 years or older [41], stool
DNA-based meSDC2 LTE-qMSP test has a low positive
predictive value (PPV) of 4.6% and a high negative pre-
dictive value (NPV) of 99.9%.
In our preliminary study, SDC2 methylation-positive
was very frequently detected about 85% in tissues of gas-
tric cancer, whereas it was not detected in other solid
cancers (data not shown). Aberrant SDC2 methylation
was also associated with Lauren classification subtype in
early gastric tumorigenesis [42]. Therefore, we included
gastric cancer patients to determine whether SDC2
methylation was detectable in stool samples from gastric
patients. For gastric cancer patients, detection rate of
SDC2 methylation was as low as 30.4%. This low detec-
tion rate of methylated SDC2 in stool DNA implies that
DNA from cells exfoliated by gastric mucosa is not eas-
ily detected in stool specimen. To determine CRC-spe-
cific methylation of SDC2, we also enrolled liver cancer
patients. For liver cancer patients, detection rate of
methylated SDC2 was as low as 30%. This low percent-
age of SDC2 methylation-positive suggests its low false
positivity for liver cancer. On the other hand, consider-
ing that not all gastric and liver cancer patients were
verified with colonoscopy as colorectal neoplasm-free,
SDC2 methylation-positive in those patients might
Fig. 4 Results of stool DNA-based SDC2 methylation test. a ROC curve was plotted for CRC patients vs. subjects with NED. AUC is indicated. b
Sensitivity of SDC2 methylation test for detecting CRC according to clinical stages. Percent of samples with detectable methylated SDC2 DNA
using 1/2 algorithm is depicted by solid bars
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indicate that they have colorectal neoplasm. To address
this, colonoscopy-verified gastric and liver cancer pa-
tients need to be tested in the future.
Imperiale et al. [15] have reported that multi-target
stool DNA test (Cologuard) has sensitivity of 92% for
detecting CRC with PPV of 3.7%. Its specificity for sub-
jects with negative results on colonoscopy was 90% with
NPV of 99.9%. For subjects with NAs, non-neoplastic
findings, and negative results on colonoscopy, the speci-
ficity was 87%. These results are comparable to our test
results. However, multi-target stool DNA test is
relatively expensive. It requires complicated analytical
procedures due to the use of multiple markers and
whole stool collection. Compared to multi-target stool
DNA test, our stool DNA-based meSDC2 LTE-qMSP
test has several features including the use of single
methylation biomarker, availability of transportation of
stool samples in preservative buffer at ambient
temperature, relative simplicity, and the use of partial
stool collection.
To effectively reduce CRC mortality, the test must
have high sensitivity because the primary aim of screen-
ing test is to detect cancer [43]. Because SDC2 methyla-
tion was not detectable in most subjects with NED,
combination of SDC2 gene with BMP3, NDRG4, or
other genetic and epigenetic biomarkers may improve its
sensitivity for detecting CRC without losing specificity.
Our stool DNA-based meSDC2 LTE-qMSP test had
the same high sensitivity for detecting CRC as Colo-
guard. In terms of false positive rate, NPV of our test
was comparable to that of Cologuard (99.9%) and FIT
(99.7%), indicating that a negative methylation test
result can provide similar information on the absence
of CRC.
Meanwhile, MethHC database revealed that SDC2 was
frequently methylated in tissues from colorectal and gas-
tric cancers, but less frequently or unmethylated in most
of the other solid tumors or normal tissues from patients
of European continental origin [44]. Thus, SDC2 methy-
lation does not seem to have ethnic difference.
This study has several limitations. The number of
samples representing precancerous lesions of CRC was
insufficient to evaluate its diagnostic value. Thus, more
patients in this group need to be tested in future studies.
Further studies are also needed to perform meSDC2
LTE-qMSP test using stool DNA samples from patients
with inflammatory bowel disease (IBD) to determine the
potential influence of exfoliation of methylated SDC2
DNA from small neoplasms in IBD on test results. The
present study had retrospective cases with prospective
control composite design. Therefore, multi-center
prospective studies are needed for intensive evaluation
of stool DNA-based meSDC2 LTE-qMSP test in screen-
ing setting. Furthermore, testing intervals and
cost-effectiveness of stool DNA-based SDC2 methylation
test in CRC screening setting should be further consid-
ered in the future.
In conclusion, this study demonstrated that stool
DNA-based meSDC2 LTE-qMSP test had a high diag-
nostic value for early detection of CRC. Our results
imply that SDC2 methylation test is a new potential
diagnostic test for CRC using stool samples noninva-
sively. Further prospective cohort studies will be needed
to determine the clinical utility of this test for
population-based CRC screening.
Table 5 Detection rate (%) of SDC2 methylation in stool DNA
from patients
Diagnosis No. of samples No. of SDC2 methylation detected (%)
Adenomas 44 12 (27.3)
NA (< 1.0 cm) 41 10 (24.4)
AA (≥ 1.0 cm) 3 2 (66.7)
P valuea 0.360
CRC 245 221 (90.2)
Sex
Male 133 119 (89.5)
Female 112 102 (91.1)
P valuea 0.675
Age
≤ 49 36 33 (91.7)
50–59 62 54 (87.1)
60–69 79 74 (93.7)
≥ 70 68 60 (88.2)
P valuea 0.544
Clinical stage
0 3 3 (100)
I 55 47 (85.5)
II 70 64 (91.4)
III 96 86 (89.6)
IV 21 21 (100)
P valueb 0.413
Tumor location
Ascending 34 28 (82.4)
Transverse 11 8 (72.7)
Descending 6 6 (100)
Sigmoid 91 85 (93.4)
Rectum 90 83 (92.2)
Others 13 11 (84.6)
P valueb 0.108
Gastric cancer 23 7 (30.4)
Liver cancer 10 3 (30.0)
aP value was calculated by Chi-square test
bP values were calculated by Fisher’s exact test
Han et al. Clinical Epigenetics           (2019) 11:51 Page 9 of 11
Abbreviations
AA: Advanced adenoma; AUC: Area under ROC curve; CI: Confidence interval;
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